| 14.37 Delayed Data As of Aug 16 |  -0.22 / -1.51%Today’s Change | 9.31 Today|||52-Week Range 17.98 | +34.42% Year-to-Date |
| Dicerna Pharmaceuticals Inc (DRNA) Q2 2019 Earnings Call Transcript Aug 09 / MotleyFool.com - Paid Partner Content |
| Previous close | 14.59 |
| Today’s open | 14.77 |
| Day’s range | 14.20 - 15.03 |
| Volume | 504,973 |
| Average volume (3 months) | 393,000 |
| Market cap | $928.5M |
| Earnings growth (last year) | +56.35% |
| Earnings growth (this year) | +21.63% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +171.23% |
| P/E ratio | NM |
| Price/Sales | 96.27 |
| Price/Book | 4.62 |
| Today’s change | Today’s % change | |
|---|---|---|
| NGMNGM Biopharmaceutica... | -0.39 | -2.55% |
| NSTGNanoString Technolog... | +0.99 | +3.72% |
| TWSTTwist Bioscience Cor... | +0.84 | +2.92% |
| STOKStoke Therapeutics I... | +0.87 | +2.90% |
| Next reporting date | November 11, 2019 |
| EPS forecast (this quarter) | -$0.25 |
| Annual revenue (last year) | $6.2M |
| Annual profit (last year) | -$88.9M |
| Net profit margin | -1,438.68% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Douglas M. Fambrough |
SVP-Operations & Alliance Management David W. Miller |
Corporate headquarters Cambridge, Massachusetts |
